UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

27 UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

Mar

24 UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

Mar

16 3 in 3: Advancing hope for rare and ultra-rare disease communities, one innovation at a time

Mar

11 BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

Mar

10 Innovation Equals Access: How UCB Delivered for Patients in 2025

Feb

04 More than Medicine: UCB's Holistic Approach to Supporting MG Patients

Dec

04 UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

Dec

03 Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program

Nov

04 Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Nov

03 U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Categories

Archives

Mar

27

UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

Mar

24

UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

Mar

16

3 in 3: Advancing hope for rare and ultra-rare disease communities, one innovation at a time

Mar

11

BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

Mar

10

Innovation Equals Access: How UCB Delivered for Patients in 2025

Feb

04

More than Medicine: UCB's Holistic Approach to Supporting MG Patients

Dec

04

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

Dec

03

Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program

Nov

04

Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Nov

03

U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Choose a Country

UCB in the U.S.

Patients

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Mar

27

UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa

Mar

24

UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

Mar

16

3 in 3: Advancing hope for rare and ultra-rare disease communities, one innovation at a time

Mar

11

BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50

Mar

10

Innovation Equals Access: How UCB Delivered for Patients in 2025

Feb

04

More than Medicine: UCB's Holistic Approach to Supporting MG Patients

Dec

04

UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting

Dec

03

Bridging Strategy and Innovation: Leadership in Action through the AES BRIDGE Program

Nov

04

Elevating the lives of people impacted by thymidine kinase 2 deficiency (TK2d)

Nov

03

U.S. FDA approves KYGEVVI™ (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)

Choose a Country

UCB in the U.S.

Patients

Innovation

UCB Worldwide

Disease Areas

Sustainability

Newsroom

Contact